The estimated Net Worth of Snehal Patel is at least $77.8 Milion dollars as of 6 August 2024. Ms Patel owns over 2,000 units of Greenwich LifeSciences stock worth over $77,263,044 and over the last 4 years she sold GLSI stock worth over $0. In addition, she makes $507,482 as CEO i CFO & Director at Greenwich LifeSciences.
Ms has made over 60 trades of the Greenwich LifeSciences stock since 2020, according to the Form 4 filled with the SEC. Most recently she bought 2,000 units of GLSI stock worth $27,620 on 6 August 2024.
The largest trade she's ever made was buying 174,825 units of Greenwich LifeSciences stock on 13 June 2024 worth over $2,499,998. On average, Ms trades about 9,257 units every 23 days since 2020. As of 6 August 2024 she still owns at least 5,534,602 units of Greenwich LifeSciences stock.
You can see the complete history of Ms Patel stock trades at the bottom of the page.
Snehal S. Patel is the CEO, CFO & Director at Greenwich LifeSciences.
As the CEO i CFO & Director of Greenwich LifeSciences, the total compensation of Ms Patel at Greenwich LifeSciences is $507,482. There are no executives at Greenwich LifeSciences getting paid more.
Ms Patel is 56, she's been the CEO i CFO & Director of Greenwich LifeSciences since . There are 4 older and 2 younger executives at Greenwich LifeSciences. The oldest executive at Greenwich LifeSciences, Inc. is Dr. Frank Joseph Daugherty M.D., 70, who is the Chief Medical Officer & Director.
Snehal's mailing address filed with the SEC is C/O GREENWICH LIFESCIENCES, INC., 3992 BLUEBONNET DR., BUILDING 14, STAFFORD, TX, 77477.
Over the last 4 years, insiders at Greenwich LifeSciences have traded over $0 worth of Greenwich LifeSciences stock and bought 654,896 units worth $6,960,565 . The most active insiders traders include Snehal Patel, Kinnary Patel oraz Kenneth Hallock. On average, Greenwich LifeSciences executives and independent directors trade stock every 16 days with the average trade being worth of $124,412. The most recent stock trade was executed by Snehal Patel on 6 August 2024, trading 2,000 units of GLSI stock currently worth $27,620.
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Greenwich LifeSciences executives and other stock owners filed with the SEC include: